Int. j. adv. multidisc. res. stud. 2024; 4(6):917-921

Received: 23-10-2024
Accepted: 03-12-2024

International Journal of Advanced Multidisciplinary Research and Studies

ISSN: 2583-049X

Enhancement of Low Solubility and Low Permeability Drug Azithromycin Using Crystallization Techniques

[1] Sonam Pandey, [2] Tanuj Pandey, [3] Sameer Khan, [4] Suchita Wamankar

[1, 2, 3] Rungta Institute of Pharmaceutical Sciences, Kurud-Kohka, Bhilai, Chhattisgarh, 490024, India

[4] Associate Professor, Rungta Institute of Pharmaceutical Sciences, Kohka, Bhilai, 490024, Chhattisgarh, India

Corresponding Author: **Suchita Wamankar**

Abstract

Azithromycin, a macrolide antibiotic, has poor solubility and low bioavailability, limiting its therapeutic effectiveness. This review explores crystallization techniques- — cooling crystallization to enhance its solubility and permeability. These methods improve dissolution rates, bioavailability, and permeability across biological membranes. Challenges like stability, regulatory concerns, and manufacturing scalability are discussed. Future research should focus on refining these techniques and combining them with other delivery strategies to optimize Azithromycin's clinical efficacy.

Keywords: Azithromycin, Low Solubility, Low Permeability, Crystallization Techniques, Polymorph Modification

1. Introduction

1.1 Crystallization Techniques

In pharmaceutical development, bioavailability plays a critical role in determining the effectiveness of drug therapies. Many drugs, especially those with poor water solubility, struggle to reach their intended therapeutic levels in the bloodstream due to low bioavailability. Crystallization has emerged as a key technique to address this issue, offering a means to modify the physical properties of drug molecules and enhance their bioavailability [1].

This review provides an overview of the role of bioavailability in drug development, the importance of crystallization in this context, and an in-depth look at the advantages, disadvantages, and crystallization methods that are being applied to improve drug delivery [2].

1.2 Bioavailability

Definition

Bioavailability refers to the proportion of a drug that enters the systemic circulation in its active form after administration, ultimately becoming available for therapeutic action. Oral bioavailability is often limited by poor water solubility, which hinders dissolution in the gastrointestinal tract, or by degradation during first-pass metabolism [3].

Importance

Optimizing bioavailability is crucial for ensuring that the drug reaches sufficient concentration levels in the blood to exert its therapeutic effect. This becomes especially important for drugs with poor solubility, as their limited absorption may require higher doses, leading to potential side effects.

1.3 Crystallization

Definition

Crystallization is the process by which solid crystals are formed from a solution, melt, or vapor. It is a purification technique commonly used in chemical and pharmaceutical industries to obtain pure solid forms of a substance. By controlling the size, shape, and polymorphic form of drug crystals, crystallization techniques can enhance the bioavailability of poorly soluble drugs [4].

Role in Bioavailability

The physical properties of drug crystals, such as particle size, surface area, and morphology, influence the dissolution rate, and thus, bioavailability. Smaller crystals with higher surface area dissolve more quickly, improving absorption in the gastrointestinal tract [5].

1.4 Advantages of Crystallization Techniques

1. **Enhanced Solubility:** Crystallization allows for the creation of smaller, more soluble particles, facilitating faster dissolution and absorption [6].
2. **Purity and Stability:** It helps in purifying drugs by removing impurities and stabilizing the crystalline form, which is essential for consistent drug performance.
3. **Cost-Effectiveness:** Crystallization is often less expensive than alternative methods such as complex formulation strategies.
4. **Polymorphism Control:** It enables control over different polymorphic forms, ensuring that the most bio-available and stable form of the drug is produced.

1.5 Disadvantages of Crystallization Techniques

1. **Complexity of Polymorphism:** The presence of multiple polymorphs can complicate the process, as different forms of the same drug may have varying solubilities and bioavailability [7].
2. **Energy-Intensive:** Some crystallization processes require high energy input, making them less efficient.
3. **Environmental Concerns:** Certain crystallization methods involve the use of organic solvents, which can be harmful to the environment and require careful handling and disposal [8].
4. **Process Control Challenges:** Maintaining precise control over factors like temperature, solvent concentration, and cooling rate is essential but difficult in large-scale production.

1.6 Crystallization Techniques/Methods

Several methods are employed to achieve optimal crystallization for bioavailability improvement:

1. **Cooling Crystallization:** In this method, a supersaturated solution is cooled to induce crystal formation. The cooling rate can influence the size and quality of the crystals [9].
2. **Anti-Solvent Crystallization:** This method involves adding a non-solvent to a solution, causing the solute to precipitate out as crystals. It is useful for drugs that are poorly soluble in water.
3. **Sono crystallization:** Ultrasonic waves are used to promote nucleation and control crystal size. This technique is beneficial for achieving uniform crystal size, enhancing dissolution rates [10].
4. **Polymorphic Crystallization:** Controlling polymorphism is critical as different crystal forms (polymorphs) can exhibit varying solubilities and bioavailability. Crystallization methods that specifically target stable, bioavailable polymorphs can optimize drug performance.
5. **Supercritical Fluid Crystallization:** Supercritical fluids (e.g., supercritical CO_2) are used to dissolve and recrystallize compounds, offering fine control over particle size and distribution [11].
6. **Microwave-Assisted Crystallization:** This technique uses microwave radiation to induce crystallization, allowing faster crystallization and better control of crystal morphology.

2. Azithromycin

Azithromycin is a widely prescribed macrolide antibiotic known for its broad-spectrum activity against bacterial infections, including respiratory, skin, and soft tissue infections. It has become a cornerstone in antimicrobial therapy due to its long half-life, excellent tissue penetration, and convenient dosing regimen. However, despite its therapeutic benefits, azithromycin faces significant biopharmaceutical challenges. Classified as a Biopharmaceutical Classification System (BCS) Class II drug, it exhibits low aqueous solubility, which limits its dissolution in the gastrointestinal tract, and moderate permeability, which can affect its systemic absorption and bioavailability. These limitations often result in suboptimal therapeutic outcomes, particularly in cases requiring rapid or consistent drug delivery [12].

The poor solubility of azithromycin stems from its intrinsic physicochemical properties, including its high molecular weight and lipophilicity. This creates hurdles in achieving efficient drug absorption and necessitates higher doses, potentially leading to side effects or drug resistance. Moreover, its limited permeability adds to the complexity of formulating effective drug delivery systems. Addressing these challenges is critical to improving azithromycin's therapeutic efficacy and optimizing its pharmacokinetic profile.



Fig 1: Structure of Azithromycin

Need for Enhancement:

- Despite azithromycin's effectiveness, its formulation challenges (such as low solubility) often necessitate the use of **excipients** to improve its pharmacokinetic properties.
- **Excipients** can play a critical role in improving the solubility, stability, and permeability [13] of azithromycin.

Azithromycin Solubility Challenges

- **Chemical and Physical Properties**:
  - Azithromycin has poor aqueous solubility, which limits its absorption in the gastrointestinal (GI) tract.
  - Poor solubility is a major cause of variability in the drug's bioavailability.

3. Strategies for Enhancing Azithromycin Solubility and Bioavailability

3.1 Cyclodextrins and Inclusion Complexes

- **Cyclodextrin Overview:**
  - Cyclodextrins (CDs) are cyclic oligosaccharides that can encapsulate hydrophobic drugs in their hydrophobic cavities, improving their solubility and stability.
  - **β-cyclodextrin** and its derivatives (e.g., hydroxypropyl-β-cyclodextrin) are particularly effective at enhancing the solubility of poorly soluble drugs like azithromycin [14].
- **Mechanism of Action:**
  - Cyclodextrins can form **inclusion complexes** with azithromycin by inserting the drug's hydrophobic portions into their cavities, preventing crystallization and improving solubility.
  - The solubility enhancement occurs due to the reduction of drug aggregation and stabilization of the drug in a more soluble form.
- **Application in Azithromycin Formulations:**
  - Various studies have explored the use of **β-cyclodextrin** or **hydroxypropyl-β-cyclodextrin** to improve azithromycin's solubility.
  - The **inclusion complex** formulation enhances the dissolution rate of azithromycin, increasing its absorption in the GI tract.
  - **Cooling crystallization**, a technique where the temperature is lowered to facilitate the formation of inclusion complexes, can be used to increase the stability of the complex and optimize drug release [15].

3.2 Fatty Acids and Permeability Enhancers (e.g., Sodium Caprate)

- **Sodium Caprate as a Permeability Enhancer:**
  - Sodium caprate is a medium-chain fatty acid that is known to enhance the permeability of drugs across the gastrointestinal mucosa.
  - It acts by disrupting the lipid bilayer of the intestinal membrane, increasing the absorption of poorly absorbed drugs [16].



Fig 2: Sodium Caprate

- **Mechanism of Action:**
  - Sodium caprate increases drug permeability by improving the **lipophilicity** of the drug-excipient complex and increasing membrane fluidity.
  - This excipient enhances the **intestinal permeability** of azithromycin by interacting with the enterocyte membrane, facilitating easier drug entry into the bloodstream.
- **Combination with Cyclodextrins:**
  - When used in combination with cyclodextrins, sodium caprate can improve both solubility and permeability.
  - This combination can be particularly useful for enhancing both the **absorption** and **bioavailability** of azithromycin.
  - **Solid dispersion systems** combining azithromycin, cyclodextrins, and sodium caprate have been studied to optimize the drug's pharmacokinetic properties [17].

3.3 Solid Dispersion Systems

- **Solid Dispersion Technique:**
  - Solid dispersion involves dispersing the drug (in this case, azithromycin) in a water-soluble carrier (e.g., polyethylene glycol) or a combination of excipients.
  - This technique increases the **surface area** of the drug, allowing for faster dissolution and improved bioavailability.
  - Cyclodextrins and sodium caprate can be incorporated into solid dispersions to further enhance drug release and absorption.
- **Advantages:**
  - Solid dispersions improve the **dissolution rate** and **bioavailability** of azithromycin, especially when used with permeability enhancers like sodium caprate.
  - This strategy is effective for **oral dosage forms** where rapid drug release is essential for therapeutic effectiveness [18].

3.4 Future Directions

Advancing the solubility and permeability of azithromycin using crystallization techniques opens numerous opportunities for future research and innovation. Below are some key directions that could further enhance the effectiveness of such approaches [19]:

1. Exploration of Novel Crystallization Techniques

- **Mechanochemistry:** The use of mechanical energy to induce cocrystallization or polymorph transformations without solvents. This sustainable and scalable approach could lead to eco-friendly drug manufacturing [20].
- **Microfluidics:** Employing micro-scale flow systems to precisely control crystallization parameters, enabling uniform particle size distribution and rapid optimization of crystal properties.
- **Spray Freeze-Drying:** A combination of spray drying and freeze-drying to produce ultra-fine particles with enhanced dissolution rates.
- **Focus on Patient-Centric Formulations [21].**
- Development of fast-dissolving or orally disintegrating tablets using crystallized azithromycin forms, enhancing patient compliance.
- Customized dosage forms, such as pediatric or geriatric-friendly formulations, utilizing improved solubility and bioavailability.
- **Biocompatible and GRAS Coformers.**
- Further investigation into Generally Recognized as Safe (GRAS) coformers for cocrystal formation, ensuring

safety, regulatory acceptance, and patient compatibility.

- **Long-Term Stability Studies.**
- Extensive studies on the stability of polymorphic forms, cocrystals, and amorphous formulations under various storage conditions to ensure consistent therapeutic performance and shelf life.

4. Conclusion

By combining **cooling crystallization** with the use of **cyclodextrins** and **sodium caprate**, it is possible to enhance both the solubility and permeability of a drug formulation. Cyclodextrins will improve the solubility through complex formation, while sodium caprate can enhance the permeability, potentially improving bioavailability. This method could be particularly useful in formulations targeting oral delivery of poorly soluble or poorly absorbed drugs.

If you're preparing a paper or a study based on this, focusing on the interactions between cyclodextrins and sodium caprate during crystallization, as well as their synergistic effects on solubility and permeability, would provide valuable insights for drug formulation strategies.

5. Acknowledgement

The authors thankful to Rungta Institute of Pharmaceutical Science, Bhilai, Chhattisgarh for providing necessary facilities and database.

6. Conflict of Interest

The authors declare that no conflict of interest of any financial or other issues.

7. References

1. Kumari L, Choudhari Y, Patel P, Gupta GD, Singh D, Rosenholm JM, *et al*. Advancement in solubilization approaches: A step towards bioavailability enhancement of poorly soluble drugs. Life. 2023; 13(5):1099. Doi: https://doi.org/10.3390/ life13051099
2. Patel K, Shah S, Patel J. Solid dispersion technology as a formulation strategy for the fabrication of modified release dosage forms: A comprehensive review. DARU Journal of Pharmaceutical Sciences. 2022; 30(1):165-189. Doi: doi.org/10.1007/ s40199-022-00440-0.
3. Attia MS, Hasan AA, Ghazy FE, Gomaa E, Attia M. Solid dispersion as a technical solution to boost the dissolution rate and bioavailability of poorly water-soluble drugs. Indian Journal of Pharmaceutical Education and Research. 2021; 55(13):103. Doi: doi. org/10.5530/ijper.55.2s.103.
4. Sareen S, Joseph L, Mathew G. Improvement in solubility of poor water-soluble drugs by solid dispersion. International Journal of Pharmaceutical Investigation. 2012; 2(1):12. Doi: doi.org/10.4103/2230- 973X.96921
5. Savjani KT, Gajjar AK, Savjani JK. Drug Solubility: Importance and Enhancement Techniques. International Scholarly Research Notices. 2012; 2012:1-10. Doi: doi.org/10.5402/2012/195727.
6. Srivastava A, Khan MA, Bedi S, Bhandari U. A Review on Different Solubility Enhancement Techniques of Ticagrelor. International Journal of Pharmaceutical Investigation. 2023; 13(1).
7. Varandal AB, Magar DD, Saudagar RB. Different approaches toward the enhancement of drug solubility: A review. Journal of Advanced Pharmacy Education and Research. 2013; 3(4- 2013):415-426.
8. Zhang X, Xing H, Zhao Y, Ma Z. Pharmaceutical dispersion techniques for dissolution and bioavailability enhancement of poorly water-soluble drugs. Pharmaceutics. 2018; 10(3):74. Doi: https:// doi.org/10.3390/pharmaceutics10030074
9. Bhalani DV, Nutan B, Kumar A, Singh Chandel AK. Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics. Biomedicines. 2022; 10:2055 doi: doi.org/10.4103/2231-4040.72262.
10. Tran P, Pyo YC, Kim DH, Lee SE, Kim JK, Park JS. Overview of the manufacturing methods of solid dispersion technology for improving the solubility of poorly water-soluble drugs and application to anticancer drugs. Pharmaceutics. 2019; 11(3):132. Doi: doi.org/10.4103/2231-4040.72262.
11. Salunke S, O'Brien F, Tan DC, Harris D, Math MC, Ariën T, *et al*. Oral drug delivery strategies for development of poorly water soluble drugs in paediatric patient population. Advanced Drug Delivery Reviews. 2022; 190:114507. Doi: https://doi. org/10.1016/j.addr.2022.114507
12. Paudel A, Worku ZA, Meeus J, Guns S, Van den Mooter G. Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: Formulation and process considerations. International Journal of Pharmaceutics. 2013; 453(1):253-284.
13. Davis M, Walker G. Recent strategies in spray drying for the enhanced bioavailability of poorly water-soluble drugs. Journal of Controlled Release. 2018; 269:110-127. Doi: https://doi.org/10.1016/j. jconrel.2017.11.005 18. Wani SU, Kakkar V, Gaut
14. Wadhwa S, Singhl S, Rawat S. Journal of Pharmaceutical and Biomedical Sciences. 2016; 06(10):551. Doi: https://doi.org/10.20936/JPBMS/160289
15. Aakeröy CB, Forbes S, Desper J. Journal of the American Chemical Society. 2009; 131(47):17048. Doi: https://doi.org/10.1021/ja907674c
16. Sekhon BS. ARS Pharmaceutica. 2009; 50(2):99.
17. Schultheiss N, Newman A. Crystal Growth and Design. 2009; 9(6):2950. Doi: https://doi.org/10.1021/cg900129f
18. Adeli E. Brazilian Journal of Pharmaceutical Sciences. 2016; 52(1):1. Doi: https://doi.org/10.1590/S1984-82502016000100002
19. Al-Hakkani MF. SN Applied Sciences, 1, Article, 2019, 222. Doi: https://doi.org/10.1007/s42452-019- 0237-6
20. Fukte SR, Wagh MP, Rawat S. International Journal Pharmacy and Pharmaceutical Sciences. 2014; 6(7):9.
21. Huang NC. Engineering Cocrystal Solubility and Stability Via Ionization and Micellar Solubilization. Doctoral Dissertation, University of Michigan, 2011.
22. Adeli E. The Journal of Supercritical Fluids. 2014; 87(3):9. Doi: https://doi.org/10.1
23. Hu L, Pan J, Liu C, Xu H, Luo L. Preparation, characterization and taste-masking properties of microspheres containing azithromycin. J. Pharm. Pharmacol. 2009; 61(12):1631-1635. Doi: 10.1211/jpp/61.12.0007, Article CAS Google Scholar.
24. Ishizaka T, Okada S, Takemoto E, Tokuyama E, Tsuji E, Mukai J, *et al*. The suppression of enhanced

bitterness intensity of macrolide dry syrup mixed with an acidic powder. Chem. Pharm. Bull. (Tokyo). 2007; 55(10):1452-1457. Article CAS Google Scholar
25. Schmidt LE, Dalhoff K. Food-drug interactions. Drugs. 2002; 62(10):1481-1502. Article CAS Google Scholar
26. Bakheit AH, Al-Hadiya BM, Abd-Elgalil AA. Azithromycin. Profiles Drug SubstExcipRelatMethodol. 2014; 39:1-40. Doi: 10.1016/b978-0-12-800173-8.00001-5, Article CAS Google Scholar.
27. Harrison TS, Keam SJ. Azithromycin extended release: A review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US. Drugs. 2007; 67(5):773-792. Article CAS Google Scholar.
28. Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem. Rev. 1998; 98(5):2045-2076. Article CAS Google Scholar.
29. Carrier RL, Miller LA, Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J. Control. Release. 2007; 123(2):78-99. Doi: 10.1016/j.jconrel.2007.07.018 Article CAS Google Scholar
30. Folch-Cano C, Yazdani-Pedram M, Olea-Azar C. Inclusion and functionalization of polymers with cyclodextrins: Current applications and future prospects. Molecules. 2014; 19(9):14066-14079. Doi: 10.3390/molecules190914066 Article Google Scholar
31. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: Past, present and future. Nat. Rev. Drug Discov. 2004; 3(12):1023-1035. Doi: 10.1038/nrd1576 Article CAS Google Scholar